Singapore markets closed

GlaxoSmithKline plc (GSK)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
39.26-0.21 (-0.53%)
At close: 4:00PM EDT

39.26 0.00 (0.00%)
After hours: 4:57PM EDT

Sign in to post a message.
  • E
    BRUSSELS, Sept 18 (Reuters) - The European Union has agreed an advance purchase agreement with Sanofi and GlaxoSmithKline to buy the companies' potential COVID-19 vaccine, according to a tweet from European Health Commissioner Stella Kyriakides.

    The agreement is the second such deal struck by the European Union. Kyriakides said she was hosting the signature of the contract.

    The deal, for all 27 EU countries, covers the purchase of 300 million doses.

    In return for the right to the doses, the European Commission will finance part of the upfront costs faced by vaccine producers. The vaccine doses themselves would be bought by EU countries. (Reporting by Philip Blenkinsop and Jan Strupczewski, editing by Marine Strauss)
  • K
    Honestly, GSK has known 5 years of steady revenue and earnings growth and the share price hasn't moved an inch.

    And although revenue is down slightly year to date, we can expect GSK as the largest vaccine maker partnering with sanofi, the third largest vaccin maker to play a big part in the development, production and distribution of a potential covid vaccine.

    It's not exactly been a top performer in my portfolio, but I'm adding, it looks really cheap atm.
  • J
    Honestly this is such a good pipeline and would be one of my fav stocks out of the 40 bios that I have, but I feel that this stock gets the best of the best possible news and it is still flat every day. I decided to sell because I worried about missed opportunity since other stocks seem to rise just with the smallest amount of speculation. I do plan to buy back in...will likely be the same price exited it at.
  • K
    Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate Pre-clinical studies show promising...
    Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate Pre-clinical studies show promising...
  • T
    gsk will have its day soon my friends
  • B
    Vir and GSK start Phase 2/3 trial for experimental COVID-19 treatment
    Published: Aug. 31, 2020 at 8:50 a.m. ET
  • P
    Big money shorting GSK to buy shares cheap. Great dividend & vaccine stock. Big money shaking 🌳
  • M
    Mr. Buddah
    Nvta morgan 38 tgt, getting stronger as day drags on.

    U x i n, nkla come back. Most of next to weeks.
  • E
    Great research by Zacks:

    "Value investors will likely look at more than just these metrics, but the above data helps show that GlaxoSmithKline is likely undervalued currently. And when considering the strength of its earnings outlook, GSK sticks out at as one of the market's strongest value stocks".
  • B
    GSK declares FDA advisory committee votes for positive advantage/chance profile for belantamab mafodotin for patients with relapsed/refractory numerous myeloma. Meanwhile, this company could deliver a substantial investment opportunity, especially with the Gold Rush well under way. Read here:
    Gold Stocks Are Hot, Gold Keeps Inching Higher In Price, Here Is Why?
  • M
    I'm newer so bare with me..
    when nvax is around 20.00 it gets US funding and triples overnight then runs to over 100.

    now companies like Pheizer and now GSK get funding and their stock kinda sits still..

    You guess as to why other companies don't explode like nvax when they get billions of dollars?
  • R
    When will $gsk break out of this trading range? I was hoping this last little rise would do it, but now we are back to waiting.
  • T
    The Abominable Snow Clown
    Snow Clown reiterates $45 by Halloween.
  • M
    Mr. Buddah
    So simple, offer 80.00 a share for nvta before mrk does.

    Buddah, own the best test patents hands down, 30 billion in covid revenues by 2030.

    Gsk board members, you need invitae.

  • M
    $CYDY conversation
    My several thoughts about $HGEN and recently announced participation in the BET trial ("big effect trial") funded by NIAID.
    1) Lenzilumab selection was based on the compassionate use data, not on the data from the ongoing ph3 trial. This might implicate that probably no interim report data from the ongoing ph3 trial is available, which in turn might implicate that HGEN has problems with fast patients enrolment (similarly to CYDY).
    2) It is strange why now a new ph3 trial is started (with 100 patients in each arm) when another ph3 trial (with 300 patients) is already running (started already in May). The novelty regarding this new trial is that a combination of remdesivir+lenzilumab is tested as well.
    3) Actually I do not understand why this BET trial with lenzilumab (and not only with lenzilumab) has not started several months ago as soon as promising data from compassionate use has been available. At the same time (around April-May) several other arms of such trial could have been added, including leronlimab from $CYDY (targeting CCR5) or other monoclonal antibodies targeting the same cytokine (GM-CSF) as lenzilumab - i.e. mavrilimumab from $KNSA, otilimab from $MOR / $GSK, and gimsilumab from Roivant.
    4) Of course it is a good news for HGEN that NIH is interested in lenzilumab and a bad news for CYDY if leronlimab has not been considered (but this might change). But anyway, if the data from the current leronlimab trials is positive (especially in case that the S/C trial is halted by the ethical committee), there is surely no need to start a new, NIAID funded trial.
  • V
    Much better days are coming.
  • r
    Frankfurt, Germany stock is moving upward
  • j
    Agenus will be breathing down the necks of all the biggest immuno oncology companies. This stock is a potential 5X and above by end of 2021.